Clinical Trial Update: Study of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Patients With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed After Prior Endocrine Therapy [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating BEBT-209 plus Fulvestrant versus placebo plus Fulvestrant in patients with HR+/HER2- locally advanced or metastatic breast c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• BEBT-209
• Fulvestrant (fulvestrant)

Snippet

Sponsor: BeBetter Med Inc | Conditions: HR+/HER2- Locally Advanced, Metastatic Breast Cancer | Phase 3 | Status: RECRUITING